Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study.
British Journal of Haematology.
Times cited: 5
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Times cited: 21
Current strategies for treatment of relapsed/refractory multiple myeloma.
Expert Review of Hematology.
Times cited: 37
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
Mayo Clinic Proceedings.
Times cited: 1